Waypoint puts seed money into RxActuator's wearable infuser

RxActuator said on October 15th, 2026 that Waypoint Ventures has anchored its seed round, backing the relaunch of the Mini-Infuser, a wearable pump that delivers medication under a pet's skin for 48 hours. It did not disclose the amount.

The device lets a stable patient go home on a continuous-rate infusion instead of staying tethered to an IV pump in the clinic. Vets use it after surgery and for chronic pain, hospice care and antibiotics, the company says.

Waypoint is backing a product clinics already buy

RxActuator is the trade name of Journey Actuating Technologies, which bought the Mini-Infuser technology and related assets in early 2026 and relaunched the product under the RxActuator brand on October 1st. The company says more than 500 units have been used by over 90 veterinary clinics in three countries, with most volume from repeat accounts.

Founder and CEO Jeff Journey is a U.S. Air Force veteran. Waypoint's first fund leans toward leaders from the U.S. Service Academies.

General partner Jeff Walker said Journey "has taken a de-risked technology and given it the leadership, systems and commercial strategy it needed."

For scale, DeepScan raised $3.5M in April to grow its canine cfDNA test from a 100-clinic base. RxActuator is at a similar clinic count. It also has hardware to build.

The pitch to clinics is bed space and margin

The Mini-Infuser is sold only to clinics, and the storefront keeps clinic pricing behind a login. RxActuator's homepage argues that every pancreatitis patient in a cage for days is a bed that could have held a surgical case.

Its profit calculator, at default settings of an $800 daily hospitalization fee and five pancreatitis cases a month, returns $88,800 in new annual profit. That total includes "a $450 combined markup and oversight fee" per protocol.

The infuser is single use, so revenue repeats with every case. That is the model that carries vet diagnostics (consumables were 88% of point-of-care diagnostics revenue in the report we covered in May).

One small pilot carries the clinical case

RxActuator cites a 2025 Journal of Veterinary Internal Medicine pilot for an 89.5% outpatient success rate and costs about 60% to 70% below inpatient care. The study followed 19 dogs with pancreatitis, had no inpatient comparison group and was funded by CEVA Animal Health.

The company says the new money will expand manufacturing, push the device into new specialties and build infusion technology that links drug delivery to clinical outcomes. Data from a second specialty would give clinics more than one use case to buy for.

Source: RxActuator via EIN Presswire